Therapeutic effect comparison of Flupentixol Melitracen and Bailemian in the treatment of moderate and severe chronic obstructive pulmonary disease with anxiety or depression
LE Liang FENG Xuan NI Hong-yan
Department of Pharmacy,Jingdezhen First People′s Hospital
Abstract：Objective To compare the effect of Flupentixol Melitracen and Bailemian in the treatment of moderate and severe chronic obstructive pulmonary disease complicated with anxiety or depression.Methods From January 2017 to December 2019,150 patients with moderate and severe chronic obstructive pulmonary disease complicated with anxiety or depression treated in the Jingdezhen First People′s Hospital were selected as subjects.They were divided into three groups with 50 cases in each group by random number table method.The control group was given conventional symptomatic treatment,the observation group 1 was given conventional symptomatic treatment + oral Flupentixol Melitracen treatment,and the observation group 2 was given conventional symptomatic treatment + Bailemian treatment.The degree of anxiety and depression,quality of life,treatment effect and adverse reactions were compared among the three groups before and after 4 weeks of treatment.Results Comparison ofthe scores of hospital anxiety and depression scale(HADS),chronic obstructive pulmonary disease assessment test (CAT) and BODE index (B for body mass index,O for airflow obstruction,D for dyspnea,E for exercise ability) before treatment among the three groups showed no statistically significant differences (P＞0.05).After 4 weeks of treatment,the anxiety subscale score in the observation group 2 was(8.11±1.03) points,depression subscale score in the observation group 2 was (8.17±1.87) points,CAT score in the observation group 2 was (24.03±2.16) points,BODE index in observation group 2 was (4.25±0.62) points,were lower than those in the observation group 1 of (11.58±2.42),(10.49±2.38) (27.17±2.54),(5.98±0.79) points,and lower than those of the control group of (12.25±3.11),(12.12±3.09),(28.36±2.63),(6.48±0.85) points,the differences were statistically significant (P＜0.05).There was no significant difference in the total incidence of adverse reactions among the three groups (P＞0.05).Conclusion Bailemian treatment can improve the negative emotions of patients with moderate and severe chronic obstructive pulmonary disease complicated with anxiety or depression,improve the quality of life of patients,and has fewer adverse reactions,so it can be used as the first choice for clinical treatment.
乐亮；冯旋；倪虹艳. 氟哌噻吨美利曲辛、百乐眠对中、重度慢性阻塞性肺疾病合并焦虑或忧郁患者的治疗效果比较[J]. 中国当代医药, 2020, 27(34): 149-152.
LE Liang ；FENG Xuan； NI Hong-yan. Therapeutic effect comparison of Flupentixol Melitracen and Bailemian in the treatment of moderate and severe chronic obstructive pulmonary disease with anxiety or depression. 中国当代医药, 2020, 27(34): 149-152.
京公网安备 11010502046607号